Genmab

08/11/19 -"Given the favourable development in FX, FY19 revenue guidance was increased by DKK300m. As operating expenses are likely to remain stable, the operating profit target also gets an uplift by a similar ..."

PDF page sample
Pages
46
Language
English
Published on
08/11/19
Download
You may also be interested by these reports :
23/02/26
Factoring in the SIFI acquisition (worth nearly 17% of Faes’ current market cap) and Faes Farma’s healthy (+16% topline growth in 9M 25) operating ...
20/02/26
After incorporating the 2025 financials, we have added a new forecast year to our model, which expects a continuation of growth at Novartis. The firm ...
20/02/26
Expanding margins despite moderate topline growth
18/02/26
After Bayer announced that it will settle most of the Roundup (glyphosate; herbicide) related class action suits (alleging Non-Hodgkin’s lymphoma, a ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO